August 2026– date –
-
China’s Ascletis Initiates Global Phase III for Oral GLP-1 Obesity Drug ASC30, Preclinical Triple Agonist FDC Shows Strong Weight Reduction
Ascletis (via news release) China Overview Chinese company Ascletis has initiated a global Phase III trial for its oral GLP-1 obesity drug, ASC30. Concurrently, the company announced positive preclinical data for its first-in-class, once... -
Revolutionizing TNBC Treatment: Datroway ADC Gains EU Nod for Immunotherapy-Ineligible Patients
Precision Medicine Online European Union Overview AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), has received European Commission approval as a first-line monotherapy for patients with ... -
Comprehensive Guide to Lipid Nanoparticles (LNPs): Key to mRNA Vaccine Success and Future RNA Therapeutic Delivery
Inside Therapeutics USA Overview Lipid nanoparticles (LNPs) are crucial nanodrug delivery systems for nucleic acids like mRNA and siRNA, vital for mRNA vaccine success and RNA therapeutics. This guide details LNP composition (ionizable l... -
Boehringer Ingelheim Initiates Phase II for BI 3034701, a Novel GLP-1/GIP/NPY2 Triple Agonist, Reshaping Obesity Treatment
Life Science Daily News USA Overview Boehringer Ingelheim initiated a Phase II trial in July 2026 for BI 3034701 (NCT07662122), a groundbreaking triple agonist targeting GLP-1, GIP, and the NPY2 receptor, signaling a new direction beyond... -
Isomorphic Labs Secures $2.9 Billion in Partnerships with Eli Lilly and Novartis, Validating AI Drug Discovery Platform
GeneOnline Taiwan Overview Isomorphic Labs, a Google DeepMind spin-out, has solidified its AI drug discovery platform's value through significant partnerships totaling $2.9 billion with Eli Lilly ($1.7B) and Novartis ($1.2B). Concurrentl... -
AI Drug Discovery Cuts Development Time to 18 Months, Insilico Medicine Achieves 99% Cost Reduction for Novel Candidates
BCC Research USA Overview AI is dramatically accelerating drug discovery, shortening the timeline from a decade to under 18 months, with Insilico Medicine identifying a drug candidate for just $2.6 million—a 99% cost saving. This rapid a... -
AlphaFold2’s Protein Structure Prediction Breakthrough Earns Nobel Prize, Igniting New Era in AI-Driven Drug Discovery
Facebook (Singularity University) UK Overview Google DeepMind's AlphaFold achieved a groundbreaking advance in protein structure prediction in 2020, leading to a Nobel Prize in 2024 for David Baker, Demis Hassabis, and John Jumper. This ... -
MDPI Accelerates Non-Coding RNA Cancer Therapy with Organ-Selective LNPs: Achieving Precise Delivery to Liver, Spleen, and Lung
MDPI Switzerland Overview Non-coding RNA (ncRNA) therapeutics in cancer are advancing, with their efficacy significantly influenced by lipid nanoparticle (LNP) characteristics like lipid composition, particle size, and surface charge. Re... -
ACE Therapeutics’ LNP Gene Editing Platform Achieves Over 90% Hepatocyte Selectivity for Lipoprotein-Targeted Cardiovascular Therapeutics
ACE Therapeutics USA Overview ACE Therapeutics' LNP-delivered gene editing platform achieves over 90% efficient hepatocyte-selective delivery for lipoprotein-targeted cardiovascular therapeutics, minimizing extrahepatic editing risks. Th... -
Swiss Bachem Invests Over $431M in 2026 to Meet Surging Global Peptide and Oligonucleotide Demand with New Facility
Pharma Manufacturing Switzerland Overview Bachem, a Swiss CDMO specializing in peptides and oligonucleotides, is undertaking a major manufacturing capacity expansion across its global network, investing between $431 million and $493 mill...
